Compare AbCellera Biologics Inc (ABCL) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares International Treasury Bond ETF — how do they compare? AbCellera Biologics Inc trades at $10 (market cap $2.99B), while iShares International Treasury Bond ETF trades at $41.29. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | IGOV | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $43.09 |
52-Week Low | $2.78 | $40.35 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
IGOV trades at $41.13, down 0.15% on the day, with a bullish technical signal driven by moving averages despite neutral oscillators. The stock shows consolidated trading near key support at $41. Financial data remains limited, but recent news highlights significant exposure to global bond market volatility through its ETF structure.
The outlook is clouded by interest rate sensitivity and inflationary pressures, posing downside risks. Investment appeal hinges on macroeconomic stability, while the primary opportunity lies in potential yield curve normalization benefiting long-duration assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
